✦ LIBER ✦

Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin : Analysis of toxicities and predictors of outcome

✍ Scribed by Tamar Safra; Susan Groshen; Susan Jeffers; Denice D. Tsao-Wei; Linyun Zhou; Laila Muderspach; Lynda Roman; C. Paul Morrow; Alexander Burnett; Franco M. Muggia

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 110 KB
Volume: 91
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20010101)91:1<90::aid-cncr12>3.0.co;2-a

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Correlation of toxicity with pharmacokin

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

✍ Olga Lyass; Beatrice Uziely; Rami Ben-Yosef; Dinah Tzemach; Norman I. Heshing; M 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

Pegylated liposomal doxorubicin and gemc

Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma : Results of a phase 2 study

✍ Giuseppe Lombardi; Fable Zustovich; Fabio Farinati; Umberto Cillo; Alessandro Vi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

Phase I study of pegylated liposomal dox

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie

Multicenter study of pegylated liposomal

Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma

✍ Uwe Wollina; Reinhard Dummer; Norbert H. Brockmeyer; Helga Konrad; J.-O. Busch; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

## Abstract ## BACKGROUND In single center studies and case reports, it was shown that pegylated liposomal doxorubicin (PEG‐DOXO) was effective as second‐line therapy for patients with cutaneous T‐cell lymphoma (CTCL). The objective of this study was to evaluate the efficacy and toxicity of single

Treatment of advanced and recurrent ovar

Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin

✍ Jerome L. Belinson; Maura McClure; Takamaru Ashikaga; Irwin H. Krakoff 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 650 KB

Phase I dose and sequencing study of peg

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies

✍ Paula M. Fracasso; Luis C. Rodriguez; Thomas J. Herzog; Carole L. Fears; Sherry 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and docetaxel have single‐agent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with ad